• Oversubscribed A$17.5M placement to fund FDA trial for autism diagnostic aid and ADHD program
• Funds will accelerate regulatory approval and commercialization of BlinkLab Dx1 platform in US and Europe
• Expansion into ADHD with BlinkLab Dx2 platform leveraging same smartphone-based technology

BlinkLab, a leading digital healthcare company focused on AI-powered diagnostic technology, has successfully completed an oversubscribed placement of A$17.5 million (before costs) to sophisticated and institutional investors. The funds will be used to support the completion of the ongoing FDA 510(k) registrational trial for the autism diagnosis using BlinkLab's Dx1 platform, the CE and MDR approval processes for BlinkLab Dx1 in Europe, the launch of a second clinical program in the U.S. using the Company's BlinkLab Dx2 platform as a diagnostic aid for ADHD, and the initiation of the FDA 510(k) registrational trial process for the use of BlinkLab Dx2 to detect ADHD. Additionally, the funds will provide additional working capital to support BlinkLab's ongoing operations, platform development, and extend the Company's patent portfolio. The successful completion of the placement represents a critical milestone for BlinkLab as the Company advances toward regulatory approval and commercialization of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism. The placement also enables BlinkLab to expand its platform into the adjacent, high-value ADHD indication, leveraging the same smartphone-based platform and AI-driven infrastructure.

The funds raised will enable BlinkLab to complete its pivotal U.S. study and progress toward FDA approval for the BlinkLab Dx1 autism diagnostic aid, while also advancing the European regulatory strategy and expanding into the ADHD market with the BlinkLab Dx2 platform. This positions the Company to address a broader spectrum of neurodevelopmental conditions and reinforces its ambition to become a leading digital diagnostics platform.